Bassil AkraCEO at AKRA TEAM GmbHAdvisor, Speaker
Profile
Dr. Bassil Akra is CEO and Owner of AKRA TEAM GmbH, a consultancy company which was founded in 2021 to support the various stakeholders in the healthcare system achieving their target in a highly regulated business area. He spent the last year consulting and supporting medical device, in-vitro diagnostic, combination device companies preparing their strategy for the EU regulations MDR 2017/745 and IVDR 2017/746. Before that, he spent many years as a subject matter expert at the biggest notified body in Europe acting in the various roles and representing locally and globally the notified body association in the various European discussion and guidance documents preparation. Dr. Akra was the Vice President of Strategic Business Development at the Global Medical Health Services of TÜV SÜD Product Service GmbH. He has long experience in leadership, business management, research, development, quality management, and regulatory approval of medical devices, combination devices, and ATMP Products. Dr. Akra played an essential role during the implementation of the medical device regulation in Europe. He was also involved in the drafting of several European guidance documents (e.g. MEDDEV, MDCG, etc.) and International Standard. He spent the last years of his career at TÜV SÜD training and educating the various stakeholders on the EU Legislations (e.g. MDD/AIMDD, MDR and IVDR), supporting their implementation towards achieving the relevant designation ensuring continuity of the healthcare system in the interest of the patient population.
Agenda Sessions
Time is Ticking...Are You Deadline Ready?
, 08:40View SessionA Deeper Dive: Article 10a and Interruption or Discontinuation of Supply of Certain Devices
, 14:15View SessionEU MDR Common Questions – The Answers!
, 17:00View SessionChairperson’s Opening Remarks: Clinical Evaluations and Investigations & Performance Evaluations
, 08:45View SessionChairperson’s Afternoon Remarks: Clinical Evaluations and Investigations & Performance Evaluations
, 14:10View Session